Apollo Medical Holdings Inc
NASDAQ:ASTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Apollo Medical Holdings Inc
NASDAQ:ASTH
|
US |
|
Al Jouf Agricultural Development Company SJSC
SAU:6070
|
SA |
|
Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873
|
CN |
Apollo Medical Holdings Inc
Apollo Medical Holdings Inc., often seen as a beacon of innovation within the healthcare industry, operates as a physician-centric, technology-powered company. It is deeply entrenched in the mission of transforming the way healthcare is delivered to populations in the United States. Essentially, ApolloMed’s framework is built around providing integrated care solutions, primarily through coordinating care for over 1.3 million patients via its network of affiliated physicians and medical groups. These medical groups and physicians usually enter into contracts with ApolloMed, which then supports them by offering population health management services, clinical expertise, and innovative technology solutions aimed at improving outcomes and operational efficiencies.
The company monetizes its operations through several revenue channels. By contracting with government and private payers, ApolloMed ensures a stable income stream through capitation arrangements and value-based payments, which incentivize quality and cost-effective care for patients. Additionally, its proprietary technology platform plays a pivotal role in enhancing clinical workflows, improving patient engagement, and ensuring better management of medical resources, thereby creating additional efficiencies. This blended model of clinical acumen intersecting with tech innovation, not only aligns the financial interests of providers with that of patients but also allows ApolloMed to bolster its bottom line, while simultaneously adhering to its commitment to high-quality patient care.
Apollo Medical Holdings Inc., often seen as a beacon of innovation within the healthcare industry, operates as a physician-centric, technology-powered company. It is deeply entrenched in the mission of transforming the way healthcare is delivered to populations in the United States. Essentially, ApolloMed’s framework is built around providing integrated care solutions, primarily through coordinating care for over 1.3 million patients via its network of affiliated physicians and medical groups. These medical groups and physicians usually enter into contracts with ApolloMed, which then supports them by offering population health management services, clinical expertise, and innovative technology solutions aimed at improving outcomes and operational efficiencies.
The company monetizes its operations through several revenue channels. By contracting with government and private payers, ApolloMed ensures a stable income stream through capitation arrangements and value-based payments, which incentivize quality and cost-effective care for patients. Additionally, its proprietary technology platform plays a pivotal role in enhancing clinical workflows, improving patient engagement, and ensuring better management of medical resources, thereby creating additional efficiencies. This blended model of clinical acumen intersecting with tech innovation, not only aligns the financial interests of providers with that of patients but also allows ApolloMed to bolster its bottom line, while simultaneously adhering to its commitment to high-quality patient care.
Revenue: Q4 revenue was $950.5 million, up 43% year-over-year; full-year 2025 revenue was $3.2 billion, up 56% YoY and at the high end of guidance.
Profitability: Adjusted EBITDA was $52.5 million in Q4 (up 50% YoY) and $205.4 million for 2025 (up 21% YoY); free cash flow for 2025 was $104.5 million.
Membership & risk: Serving 1.6 million members; management expects ~80% of revenue and >36% of membership in full-risk arrangements by end of Q1 2026 and continues disciplined, measured risk progression.
Prospect integration: Integration on track; the company now expects to achieve the high end of $12 million to $15 million annualized synergies and reports >97% PCP gross retention at Prospect.
Guidance: 2026 guidance: revenue $3.8 billion–$4.1 billion, adjusted EBITDA $250 million–$280 million, free cash flow $105 million–$132.5 million; Q1 2026 revenue $900 million–$1.0 billion, adjusted EBITDA $60 million–$70 million.
Medicare Advantage rates: Management expects Astrana to be less exposed than industry averages to the MA advanced notice changes and believes the company could see a favorable effective rate outcome versus peers.
Controls & filing: Company will file a Form 12b-25 because of a material weakness tied to acquisition/purchase accounting processes; reported results are in accordance with U.S. GAAP and no restatements were required.
